Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
Clinical trial NCT02028884 · COMPLETED
Trial details
- NCT number
- NCT02028884
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-02-20
- Primary completion
- 2018-06-06
- Enrollment
- 85
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.